Vorasidenib 40 mg daily
40 mg · ITT
grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163)
Comparator: placebo
PFS hazard ratio vs placebo (BIRC): 0.39 HR, primary analysis
time to next intervention hazard ratio: 0.26 HR, primary analysis
median time to next intervention, placebo: 17.8 months, primary analysis
median PFS, vorasidenib: 27.7 months, NEJM 2023
median PFS, placebo: 11.1 months, NEJM 2023
median PFS, extended follow-up: 44.1 months, ASCO 2026, preliminary
objective response rate, extended follow-up: 20.8%, ASCO 2026, preliminary
INDIGO · NCT04164901
Vorasidenib, non-enhancing glioma
Phase 1 doses · Single arm
recurrent non-enhancing IDH-mutant glioma (n = 22)
objective response rate: 18%, Phase 1
median PFS: 36.8 months, Phase 1
Vorasidenib Phase 1